Genmab — August 2018

[StockBull]

Godt nok en tam volumen idag. Ser us som om alle sidder på hænder inden MAIA data. Forhåbentligt kan gode data inden udgang af September bringe fornyet interesse til at investere i Genmab

[ienk1]

Genmab får milepælsbetaling fra Novo for præklinisk fremskridt

Janssen og Novo Nordisk har gjort fremskridt i programmer, der gør brug af Genmabs Duobody-teknologi, og det har givet biotekselskabet 74 mio. kr. i kassen. "Genmab bliver et stadigt bredere powerhouse for biotekinnovation," siger topchef Jan van de Winkel.

(medwatch.dk)

[mobbyduck1]

se kl 10.49

[Helge_LarsenPI-redaktør]

Tekniske analyse Novo og Genmab: https://play.borsen.dk/social/5b70e339b1ac14e30ab6c5b3

[bibob]

Ja, hvis han ikke har fået købt kan det da være han er lidt for sent ude. ;-). Måske basis for en lille opjustering Q 3 qua gode salgstal og en fortsat stabil dollar kurs. Håbe kan vi jo altid.

[jkj]

Undre mig at en milestone på 74 mill dkr, i Novo sammenarbejdet ikke udløser en børsmeddelse ?

[mobbyduck1]

det var en gang, da 74millioner var en del for Genmab:-)

[gentogen]

De er gået meget stille med det, men der var også denne: https://medwatch.dk/secure/Medicinal___Biotek/article10333812.ece

[pauly]

Genmab til sidst i indslaget TA https://play.borsen.dk/klip/5b70e339b1ac14e30ab6c5b3

[bibob]

Pauly. Helge kl 13.26.

[bikube]

Adskillige Mia. i milestones lyder da meget godt, og så giver det måske også lidt royalties bagefter.

[pauly]

ok

[Bella1]

Ser ud til at vi, stille og roligt, er "on the road again".....

[E_L]

we should still have some warrants exercised this week i imagine, but at the current price probably not that many…

[F_L]

I know that after the Callisto failure things changed on the solid side. Just have a question one step back on why Genmab was targetting that market. I know the lung cancer market is a huge market. On the other hand there are other drugs/ther being developed which are a lot cheaper. From a cost/effectiveness (Dara) point of view, was it interesting enough to target it in the first place, ie could Dara have made a big difference vs the other new medicines? Didn't look at the ph1 data in detail.

[Helge_LarsenPI-redaktør]

FL...Welcome to Proinvestor. Maybe you should find a different alias than F L. It will easily be confused with E L.

[Mcjean]

JNJ own the rights for Dara, Genmab only get Royalties and milestones so Its JNJ there decide the indikation profile........if i understand u question correct.

[F_L]

"Helge, thank you. I have no intention to post frequently.

[F_L]

@ McJean sorry I meant JNJ. It surprised me they wanted to look at Dara in lung cancer given all the other cheaper therapies that are being developed.

[Plimsoller]

God morgen